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Abstract
Chronic kidney diseases (CKD) are associated with mineral and bone diseases (MBD), including pain, bone loss, and frac-
tures. Bone fragility related to CKD includes the risk factors observed in osteoporosis in addition to those related to CKD, 
resulting in a higher risk of mortality related to fractures. Unawareness of such complications led to a poor management of 
fractures and a lack of preventive approaches. The current guidelines of the Kidney Disease Improving Global Outcomes 
(KDIGO) recommend the assessment of bone mineral density if results will impact treatment decision. In addition to bone 
density, circulating biomarkers of mineral, serum bone turnover markers, and imaging techniques are currently available 
to evaluate the fracture risk. The purpose of this review is to provide an overview of the epidemiology and pathogenesis of 
CKD-associated bone loss. The contribution of the current tools and other techniques in development are discussed. We here 
propose a current view of how to better predict bone fragility and the therapeutic options in CKD.
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Introduction
The high morbidity and mortality rates observed in progres-
sive chronic kidney disease (CKD) are tightly associated 
to the underlying metabolic bone alterations. The mineral 
and bone disorders (MBD) associated with CKD include 
bone, biochemical, and cardiovascular abnormalities in the 
same entity since they share common pathophysiological 
mechanisms. This current new definition of CKD-MBD 
aims at a better awareness of concommitant bone and car-
diovascular events and shows that common molecules are 
involved in both tissues breakdown. The initial characteriza-
tion of previously called renal osteodystrophy (ROD) was 
based on bone biopsy and is extended nowadays to bone 
markers of fragility, including biochemistry and imaging. 
Bone fragility includes all the aspects that lead to fractures, 
particularly bone volume, structure, rate of remodeling, as 
well as mineralization defects which can be also observed in 
CKD. Fractures are the end results of skeletal fragility, the 
prevention of which being a major objective. The evaluation 
of fracture risk is required in light of high mortality risk and 
hospitalization costs related to fracture in dialysis patients 
[1–5], which enhances the economic burden of CKD-MBD.
An important contribution of the Kidney Disease Improv-
ing Global Outcomes (KDIGO) 2017 revised version [6] 
compared to 2009 KDIGO CKD-MBD guidelines [7] is to 
recommend the assessment of bone mineral density (BMD) 
in case a treatment is considered, thus highlighting the need 
of a better assessment of CKD patients suffering from skel-
etal fractures. However, there is no recommendation about 
which BMD should be assessed and at which frequency 
in CKD patients as it is in osteoporotic postmenopausal 
women. Indeed, in this population, a second BMD per-
formed 3 years after the initial measurement was not asso-
ciated with improved discrimination between women who 
did and did not experience subsequent hip fracture or major 
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osteoporotic fracture beyond the baseline BMD value alone 
and should not routinely be performed [8]
Epidemiology of Skeletal Fractures in CKD
The life expectancy of CKD patients is constantly improving 
because of a better prevention and management of compli-
cations. The prevalence of skeletal fractures in the general 
population as well as in subjects with CKD has significantly 
increased in the recent years along with aging and the related 
increase in bone loss. This can be evidenced by several lon-
gitudinal studies reporting the incidence of fractures during 
the last decade [3, 9–27]. They found the fracture incidence 
to raise progressively from 15.0 to 20.5, 24.2, 31.2, and 
46.3/1000 person-years for CKD stages 1 to 2, 3a, 3b, and 
4, respectively [28]. The risk of skeletal fracture is up to 5 
times higher in individuals with an estimated glomerular 
filtration rate (eGFR) < 15 versus > 60 ml/min/1.73 m2. This 
is particularly true in CKD patients older than 65 years who 
show the highest rate of fractures, with 1/10 women and 
1/20 men experiencing at least one fracture in the subsequent 
3 years of follow-up [29]. In a recent Dialysis Outcomes 
and Practice Patterns Study (DOPPS) report, the incidence 
of skeletal fractures was significantly higher for patients 
receiving hemodialysis therapy than in the general popula-
tion with a 3.7-fold increase of the unadjusted relative risk 
of death [4].
Peripheral fractures are the best documented. The inci-
dence of hip fractures is four-fold higher for dialysis patients 
than for the general population after adjustment for age, 
gender, and ethnicity [9, 30]. Moreover, the incidence of 
hip fracture in CKD patients differs by ethnicity and sex, 
being 3 times higher for Caucasian than African-American 
[1] and twice higher for women than men [3, 21, 27, 31]. 
They are also associated with several risk factors including 
older age, low body mass index, and long dialysis vintage, 
as well as with a history of prior hip fracture [23]. A recent 
study evaluated the association between CKD stages G3–G5 
versus eGFR > 60 ml/min/1.73 m2 and the risk of a new non-
hip fracture or fragility fracture in patients with a first hip 
fracture. It found that the risk of a subsequent major non-hip 
fragility fractures following hip fracture was not increased 
in patients with CKD G3–G5 compared to eGFR > 60 ml/
min/1.73 m2. Mortality risk was higher in both hip fracture 
and non-hip fracture patients with CKD G4 and G5 [32].
The most recent and the largest epidemiologic study 
assessing the incidence and the risk factors associated with 
hip fractures is a South Korean report from 352,624 CKD 
adult subjects [33]. They found that lower eGFR and high 
urine albumin levels were associated with a higher risk of 
hip fracture. The HR for hip fracture was 1.89 among par-
ticipants with eGFRs of 30–44 and 15–29 mL/min/1.73 m2 
relative to those with an eGFR ≥ 60 mL/min/1.73 m2, respec-
tively. The HRs were 1.30 for moderate albuminuria and 
1.58 for severe albuminuria. Participants with albuminuria 
had a higher risk of hip fracture than those without albumi-
nuria, even when they belonged to the same eGFR category. 
The effects of each 10 mL/min/1.73 m2 decrease in eGFR 
were stronger with advancing albuminuria severity.
The US Medicare data for hemodialysis patients have 
recently reported a downward hip fracture incidence trends 
from 2000 to late 2009 [1], most prominent in older adults 
of both genders [34]. Indeed, the incidence of hip fracture 
increased when dialysis treatment was initiated from 1996 
to 2004 and then declined until 2009, although it remained 
higher than in 1996 [16]. The relative risk of hip frac-
tures starts to increase as early as age 55 years and is more 
increased for CKD patients with high bone turnover disease 
rather than with low bone turnover disease [23, 27]. The risk 
of skeletal fractures combines classical risk factors that are 
applied for osteoporosis in addition to those associated with 
CKD. After 4 years of dialysis, the age-standardized inci-
dence ratio of hip fracture was 9.83 (8.61, 11.2; 95% C.I.) 
for men and 8.10 (7.23, 9.07; 95% C.I.) for women [9]. Even 
in renal transplant recipients, prior dialysis vintage is asso-
ciated with increased risk of hip fracture [2, 35]. Because 
of a rare collection of vertebral fractures, the prevalence of 
this major bone fragility is poorly documented in cohort and 
dialysis registers. This has been reported to be low, ranging 
from 7 to 20% [36, 37], and only 1% of patients appear to 
have vertebral fractures based on clinical diagnosis in a sin-
gle clinical trial [38]. It is likely that this is underestimated 
because of the lack of systematic radiographic imaging or in 
the presence of spinal pain or the difficulty to differentiate 
a mild vertebral fracture from deformities as seen in Scheu-
ermann disease. A more recent analysis of a prospective 
cohort of 612 patients with 3‒5 stage CKD revealed 18% of 
vertebral fractures. After a 3-year follow-up, the prevalence 
of fractures was correlated with a poor survival and an inde-
pendent predictor of all-cause mortality [39].
The risk of mortality following a hip fracture is signifi-
cantly high in CKD patients, [40, 41] but has essentially 
remained unchanged since 1998 for either sex [31]. The 
thirty-day mortality rate after hip fracture is of 16% for CKD 
patients initiating dialysis and age > 67 years in the United 
States [16]. The hip fracture-related mortality risk is also 
two times higher with eGFR < 45 than ≥ 45 ml/min/1.73 m2 
[42]. In the French national database in 2010, a signifi-
cant higher mortality rate was observed after hip fracture 
in patients on dialysis therapy compared to those without 
dialysis, up to 12% for men and 8% for women, as well as 
a longer hospital stay in the intensive care unit [3]. Several 
major risk factors were found to be associated with those 
hip fractures, particularly the presence of cardiovascular 
diseases and dementia.
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Evaluation of Fracture Risk in CKD‑MBD
Bone strength is based on both the quantity and quality 
of bone, influenced by several factors such as the level of 
bone remodeling or the matrix composition. Bone quantity 
can be estimated by bone density while bone quality by 
the microarchitecture, both leading to a reduced mechani-
cal bone adaptation. Thus, most fractures occurring after 
a fall or a low kinetics trauma take place in a bone with 
low mechanical strength. Cumulative studies revealed 
that the high fracture risk results from the combination of 
CKD-induced changes in bone and mineral metabolism in 
addition to the classical fracture risk factors observed in 
the non-CKD population including age, gender, diabetes, 
and glucocorticoid use. Several imaging and biochemical 
markers, here below described, have demonstrated their 
usefulness to assess the fracture risk in CKD population.
Bone Mineral Density
In non-CKD patients, the reduction of BMD as measured 
by dual-energy x-ray absorptiometry (DEXA) predicts the 
fracture risk. Osteoporosis is defined by a T-score below 
2.5 standard deviations (number of standard deviations of 
BMD below the mean BMD for the young healthy popula-
tion). The relevance is limited in patients with scoliosis, 
osteoarthritis at the lumbar spine, and noteworthy in the 
presence of vascular calcifications that are frequent in 
CKD and which overestimate the BMD. Another limita-
tion of BMD and T-score is that it does cannot distinguish 
the type of ROD and cannot discriminate osteoporosis as a 
low bone mass than low bone density related to minerali-
zation defect. A meta-analysis showed that BMD is lower 
in pre-dialysis and dialysis CKD patients with fractures 
compared to those without [43]. Despite these findings, 
BMD measurement was not recommended in the 2009 
KDIGO guidelines because of inconsistency in the results 
obtained from most of cross-sectional studies and the mild 
reduction of BMD that cannot be used at the individual 
level. More recently, prospective cohort studies showed 
good predictive value of BMD for risk of peripheral frac-
ture and hip fractures in CKD stages 3-5D [12, 28, 44, 
45]. This prompted the recent 2017 KDIGO guidelines 
to recommend BMD measurement if results will impact 
treatment decisions, as advocated by the World Health 
Organization (WHO) for the general population.
Nevertheless, scarce data are available for the predic-
tion of vertebral fractures, one of the main hallmarks of 
bone fragility. Case–control studies with a small number 
of dialysis patients revealed that a low BMD at the lumbar 
spine was associated with vertebral fractures and with the 
prevalent or self-reported peripheral fractures [46]. In a 
meta-analysis of 13 studies [43], only one mentioned a 
relationship between vertebral fracture and the dialysis 
vintage, but did not find any association between BMD 
and the risk of fracture [11]. Albeit a lower discriminative 
value of BMD in CKD, recommendations of BMD meas-
urement for predicting peripheral fractures draw the atten-
tion to a better assessment of a well-recognized marker of 
fragility fractures. In addition, the Fracture Risk Assess-
ment Tool (FRAX) index is sufficient for 10-year predic-
tion of major osteoporotic fractures, assessing clinical risk 
factors together with BMD [44, 47], in particular in older 
patients with CKD stages 2–5 [47]. A recent study in 718 
Polish hemodialysis patients, who were followed up for 
two years, showed that the Polish version of FRAX > 5% 
(without the DXA examination) and some particular vari-
ables of the FRAX calculator had a sensitivity of 70.0% 
and a specificity of 69.8% as the prognostic threshold for 
major bone fractures. Again, in this study, FRAX sensitiv-
ity for bone fracture prediction was significantly higher, 
but specificity is lower than those of FRAX ≥ 10%, used 
in general Polish population. The reason for this can be 
an underestimation of bone fracture risk with FRAX in 
dialysis patients [48].
Bone diseases related to CKD represent a large spectrum 
of histological features, all associated with a high risk of 
fracture. Indeed, low BMD may be observed in osteopo-
rosis, but also in hyperparathyroidism, osteomalacia, and 
adynamic bone diseases. This difficulty of characterizing 
the bone disease requires additional evaluation in order to 
address specific treatment of the cause.
Macro and Microarchitecture of Bone
Altered hip geometry, as derived from DEXA hip meas-
urement, has been associated with the risk of fracture. 
Non-CKD women with hip fractures have thinner femoral 
cortices and longer femoral-neck axis length than women 
without fractures. Such DXA-derived cortical parameters 
were reported in patients in CKD patients [49]. Although 
hip structural values are correlated with BMD, whether 
they provide additional information independent of BMD 
and if this improves fracture prediction remains unknown 
[50]. Further investigations using the new three-dimensional 
(3D)-DXA software will be useful in CKD as previously 
shown in patients with primary hyperparathyroidism [51].
Another marker emerged recently to evaluate bone 
strength. The Trabecular Bone Score (TBS) is a gray-level 
textural index derived by an algorithm that analyzes the 
spatial organization of pixel intensity from lumbar spine 
DEXA images. TBS is not a direct measurement of bone 
microarchitecture, but it is correlated to it. TBS can be 
used to predict fractures independent of major clinical 
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risk factors or a real BMD measured in the general popu-
lation [52]. In a cohort of 1426 participants older than 
40 years and followed for a mean of 4.7 years, including 
199 patients with eGFR < 60 ml/mn/1.73 m2 (72.4% CKD 
stage 3a, 25.1% CKD stage 3b, and 2.5% CKD stage 4), 
low lumbar spine TBS was independently associated with 
increased fracture risk when kidney function was low, pro-
viding a new tool to better identify the patients at risk [53].
As discussed above, BMD measurement by DEXA is 
insufficient to assess the fracture risk partly because of a 
weak discriminating power between cortical and trabecu-
lar bone. Indeed, bone strength depends on cortical bone 
which is highly altered in CKD. Bone biopsies obtained 
from CKD patients revealed that low bone turnover is 
associated with normal cortical porosity, while high serum 
PTH levels are present with normal cortical thickness and 
high trabecular bone volume [54]. However, the biopsies 
performed were not systematic, but for research purposes, 
introducing a recruitment bias for a clear-cut interpreta-
tion. Nevertheless, assessment of cortical bone structure in 
CKD is crucial since predominantly affected by bone loss 
and highly associated with peripheral fractures at any skel-
etal sites [55]. Undoubtedly, such structural components 
are additional parameters to be included in the treatment 
decision in addition to the rate of bone remodeling and 
bone and mineral biomarkers.
Quantitative computed tomography (QCT) revealed a 
higher number of patients experiencing bone loss at the 
hip as compared with BMD measured by DEXA [56]. The 
peripheral QCT device from Stratec, which measures only 
BMD at the mid-radius and then mainly cortical bone, 
showed that high PTH, long dialysis vintage, and cortical 
BMD were significant predictors of skeletal changes [57]. 
BMD and microarchitecture assessed by high-resolution 
peripheral quantitative tomography (HRpQCT) allow a sepa-
rate measurement of cortical and trabecular bone [58] and 
help to determine the underlying mechanisms of bone loss 
[59]. In CKD stages 2–4, HRpQCT showed early impair-
ment of trabecular bone, before the onset of secondary 
hyperparathyroidism (SHPT). This could explain in part the 
high risk of fractures in early CKD [60] but also in patients 
with long CKD history [58]. HRpQCT measurements allow 
to distinguish between cortical and trabecular bone density 
in vivo. It assesses both bone volume and density in the same 
compartment, thus potentially yielding information regard-
ing bone mineralization as well. A recent study in 68 dialysis 
children with bone biopsy determination showed that 76% of 
patients had normal/high bone turnover, 13% had adynamic 
bone disease, and 11% had osteomalacia. Bone formation 
rate did not correlate with any HRpQCT determinations. 
Bone volume measurements were highly correlated between 
bone histomorphometry and HRpQCT (bone volume/tissue 
volume between the two techniques) [61]. We have also 
recently analyzed bone trans-iliac biopsies performed for 
vertebral or hip fracture in 12 adult dialysis patients and 
compared with bone microarchitecture assessed by two-
dimension histology (2D) and in  vitro microcomputed 
tomography (3D-µCT) as well as with microarchitecture 
data obtained from HRpQCT. We found that 3D-µCT was 
a reliable method for the measurement of cortical bone in 
bone biopsies. However, only HRpQCT allows discriminat-
ing patients with multiple fractures [62].
Bone loss observed in CKD stage 5D affected cortical 
BMD and thickness which is correlated with high PTH and 
dialysis vintage, but not with trabecular bone [55]. However, 
levels of neither calciotropic hormones such as PTH nor 
bone remodeling markers were associated with changes in 
trabecular density, number, and heterogeneity. These data 
have been challenged more recently by a study using bone 
biopsy data that correlated cortical BMD to biochemical 
markers [63]. Cortical BMD was negatively correlated to 
serum PTH, TRAP5b (tartrate-resistant acid phosphatase 
5b), and BSAP (bone-specific alkaline phosphatase) levels, 
suggesting that low remodeling rate is associated with higher 
bone density and strength. These controversial data are likely 
related to changes that occur at different remodeling rates, 
biomarkers reflecting the level of bone remodeling at short 
term while cortical thickness integrating remodeling rates 
for a long period. Research should address new imaging of 
the appendicular skeleton to estimate cortical bone loss [58]. 
For example, analysis of bone matrix, including collagen and 
mineral properties, should be developed [64, 65]. Despite 
the great interest of predicting the risk of fracture and identi-
fying people who will benefit from therapeutic interventions, 
most of these new tools are not widely available, as well 
as evidence of additional interest compared to DEXA [66].
Bone Biomarkers
Since several decades, PTH remains the best surrogate 
biomarker to evaluate the level of bone remodeling in 
CKD. Most CKD patients with adynamic bone disease 
displayed serum PTH level < 150 pg/mL [67] and those 
with histological SHPT show PTH values > 600 pg/ml 
[68]. Although within the KDIGO recommended PTH 
target of 2–9 the normal range, those values within the tar-
get range do not discriminate the different forms of ROD 
[69] and both high and low circulating PTH levels can be 
associated with high fracture rate and mortality risk [4, 5, 
20, 23, 36, 70–72]. Interestingly, serum PTH levels, just 
before the occurrence of a new fracture, are associated 
with the increased risk of fracture, in contrast to baseline 
or time-averaged serum PTH levels. The upper and lower 
PTH values of the U-shaped PTH curve are associated 
with a significantly increased risk of fracture as compared 
with PTH values within the recommended NKF/K-DOQI 
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target values [12]. Therefore, treatment should not be 
based on a single PTH value but rather on a trend of PTH 
within the previous months. As mentioned in the KDIGO 
2017 guidelines, “persistently” and “progressively rising” 
PTH level should be considered, rather than “above the 
upper normal limit”. Total or subtotal parathyroidectomy 
reduces serum PTH levels and subsequently bone turnover, 
improves BMD and reduces long-term risk for fractures 
in CKD stage 5D patients [73–75]. Other circulating bone 
biomarkers provide additional information of the rate of 
bone turnover and microstructure of bone. These include 
cross-linked collagen type I peptide (CTX) and tartrate-
resistant acid phosphatase 5B (TRAP5b for bone resorp-
tion, as well as bone-specific alkaline phosphatase, and 
procollagen type 1 N-terminal pro-peptide (P1NP) for 
bone formation [56]. A recent study has shown the pre-
dictive value of association of these markers and PTH to 
predict bone fragility [76]. In another recent study, not yet 
investigated for fracture prediction, a panel of 4 microR-
NAs was superior to circulating concentrations of bone-
specific alkaline phosphatase and CTX for discriminating 
low bone turnover within individual cancellous, endocorti-
cal, and intracortical bone compartments [77].
The phosphate/FGF23/alpha-Klotho axis is another deter-
minant of bone mineralization in CKD. Circulating phos-
phate levels slowly increase with the progression of CKD 
and both directly and indirectly contribute to the skeletal 
fragility associated with CKD-MBD, in part via the stimula-
tion of PTH and FGF23 production [78]. The role of serum 
phosphate as a bone fracture risk factor has been poorly 
studied. In general population, the results from the Dutch 
Rotterdam Study (RS-I, RS-II and RS-III) and the US Osteo-
porotic Fractures in Men (MrOS) study including 12,216 
patients followed up to 10.9 years showed that serum phos-
phate was significantly associated with bone fractures [79]. 
Quintiles 4 (3.3–3.5 mg/dL) and 5 (> 3.5 mg/dL) of serum 
phosphate were associated with a higher risk of incident of 
all types of fractures compared with quintile 1. In this study, 
serum phosphate was associated with fracture risk in sub-
jects without CKD and also in men with CKD. In men with 
CKD the association between serum phosphate and fracture 
risk was even stronger than in non-CKD subjects. In 2004, 
Block el al. found that serum phosphate was significantly 
associated with bone fracture-related hospitalization with a 
relative risk of 1.12 per mg/dL increase in serum phosphate 
in hemodialysis patients [80]. Unpublished data from the 
COSMOS study (Current management Of Secondary hyper-
parathyroidism: a Multicentre Observational Study) are in 
the same line, showing, in a period of 3-year follow-up, that 
high serum phosphate is associated with a higher incidence 
of bone fractures. By contrast, Aleksova et al [81] found that 
low serum phosphate was associated with a higher risk of 
bone fractures in transplanted patients.
Serum FGF23 levels significantly increase in early CKD 
stages and coincide with the decrease of 1,25OH2D [82]. 
FGF23 is mainly produced by osteocytes and osteoblasts and 
exerts its major physiological actions in the kidney, stimu-
lating urinary phosphate excretion and inhibiting calcitriol 
synthesis after binding to a complex formed by alpha-klotho 
and canonical FGF receptors. FGF23 plays an important role 
in regulating bone mineralization. In CKD stage 5D patients, 
BMD is not correlated with serum FGF23 levels [83]. How-
ever, high FGF23 and low klotho levels were found in CKD 
patients with type 2 diabetes compared to controls and even 
further in CKD with fractures [84]. High FGF23 was asso-
ciated with reduced osteoid thickness in children both with 
normal renal function and dialysis [85], through the regu-
lation of tissue non-specific alkaline phosphatase activity 
(TNAP) via FGFR-3, vitamin D, and klotho-independent 
manner. Finally, excessive FGF23 contributes to bone loss 
in CKD via an alpha-klotho-dependent mechanism and 
the stimulation of the osteoblast Wnt inhibitor Dkk1 [86]. 
Therefore, inactivation of the Wnt/b-catenin signaling path-
way by the altered phosphate/FGF23/Klotho axis may pro-
vide another autocrine/paracrine mechanism favoring bone 
loss in CKD-MBD.
Contribution of Bone Histology
Bone histomorphometry is the gold standard to evaluate 
bone abnormalities of CKD-MBD [87], although not rou-
tinely recommended because of its invasive nature and the 
limited number of specialized laboratories. Histological 
signs of high bone turnover are expected in that 85–90% 
of patients have increased serum PTH level in CKD stages 
3–5 [88, 89]. Accordingly, histological high bone turnover 
in 47.2% of patients with CKD stages 3–4 and in 61.4% 
with CKD stage 5 [90]. However, low-turnover bone dis-
ease has also been reported as being the predominant pattern 
in 2 small populations with pre-dialysis and a wide eGFR 
range (< 5 to 90 ml/min/1.73 m2) [91, 92] and in most CKD 
patients on dialysis [54, 93]. These conflicting results might 
be related to the recruitment of patients; bone biopsies being 
mostly performed in symptomatic patients with no system-
atic analysis for epidemiologic purposes are influenced by 
several confounding factors. Moreover, the lack of clear-cut 
and quantitative definition of adynamic bone disease (ABD) 
and the absence of previous labeling do not allow drawing 
clear conclusions.
In addition, CKD progression might result in changes 
from low bone turnover at earlier stages to high bone turno-
ver features at later stages [94] and there is no association 
between fracture incidence and the histological type of bone 
diseases. Finally, bone biopsy may show mineralization 
defects and osteomalacia, even in the absence of marked 
changes in circulating biomarkers. Actually, the first causes 
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of bone mineralization defect are vitamin D deficient-related 
osteomalacia, hypophosphatemia, and aluminum overload. 
Osteomalacia remains present in long-term dialysis therapy 
and remains a cause of fractures. Moreover, the use of the 
new bone nomenclature (TMV), which now adds bone min-
eralization indices to turnover and volume should contribute 
to a better definition of the classical renal osteodystrophy 
and a better estimation of fracture risk and understanding 
clinical features.
Therapeutical Management of Fractures 
in CKD
Several medications have been shown to reduce the fracture 
rate in patients with low BMD. All of them can be proposed 
for the prevention of fractures when eGFR is above 30 ml/
min/1.73 m2 after correction of 25OHD insufficiency. In 
any case, supplementation of vitamin D is strongly recom-
mended when initiate therapies regardless of kidney func-
tion. Specific cause of non-osteoporotic fractures should be 
discarded and required specific treatments. The presence 
of osteomalacia can be suggested by low serum 25OHD 
levels, long-lasting hypocalcemia or hypophosphate, and 
high alkaline phosphatase levels [95]. All the medications 
that received the approval for the prevention of fractures 
will follow the same recommendations as in non-CKD 
patients. This is the case of raloxifene, bisphosphonates, 
and denosumab, the three of them being pure inhibitors of 
bone resorption while teriparatide, the human recombinant 
PTH, increased bone resorption and formation with a posi-
tive bone balance in favor of bone formation. Treatment of 
CKD stage 4-5D patients with osteoporosis requires more 
caution and should be discussed after the correction of min-
eral biomarkers. There is no evidence that any treatment 
prevents the fracture rate in patients with low BMD alone. 
Nevertheless, the presence of major osteoporotic fracture 
occurring in skeletal sites such as vertebrae, pelvis, humerus 
and hip demonstrates a bone fragility that requires a more 
active treatment.
Most anti-fracture treatments are contra-indicated in 
patients with an eGFR < 30 ml/min. Bisphosphonates accu-
mulate in bone tissues, this being promoted with reduced 
renal clearance and subsequently might induce defects of 
bone mineralization and osteomalacia [96]. Albeit there is 
no evidence of such a deleterious effect, the use of bisphos-
phonates requires being aware of such possible complication. 
Few studies and early post hoc analyses showed increased 
BMD with bisphosphonates, but a systematic review sug-
gested that no evidence that these treatments could be help-
ful in CKD as no anti-fracture effect has been shown [97]. 
Denosumab, an anti-RANKL biologic therapy not cleared 
by the kidney, offered new opportunities for managing 
fractures. In a subgroup of 73 women with CKD stage 4, 
denosumab increased the BMD in a similar manner than in 
women with CKD stages 1–3, but the low number of patients 
did not allow to demonstrate an effect in fracture prevention 
[98]. In patients with CKD stages 4-5D with severe SHPT, 
denosumab promoted marked hypocalcemia and increased 
PTH level within the first 15 days of its administration, 
which often required calcium supplementation. Therefore, 
a close monitoring is recommended during those first weeks 
in patients with advanced CKD. A trial compared the one-
year effect of denosumab to alendronate in dialysis patients 
with low PTH and found that there was a better increase in 
BMD and improvement of bone biomarkers associated with 
denosumab [99]. In the absence of linear relation between 
BMD and fracture risk in CDK, the increase in BMD does 
not fully secure the effect on the prevention of the risk of 
fracture at short and long term. Further trials are needed 
to test the effect of such a medication in both BMD and 
fracture risk.
Recommendations for the management of fractures in 
CKD patients rely more on clinical experience than on scien-
tifically well-proven evidence (Fig. 1). First characterization 
is based on the BMD measurements, followed by the PTH 
and bone-specific alkaline phosphatase levels. In patients 
with high PTH, the reduction of SHPT improved other bio-
logical parameters and the bone status. Indeed, accounting 
for differences in baseline characteristics, multiple fractures, 
and/or events prompting discontinuation, oral cinacalcet 
efficiently reduced the rates of clinical fractures in elderly 
dialysis patients [38]. In these patients, denosumab might be 
discussed once PTH target has been achieved and that BMD 
remains significantly low [100]. The indication of a subtotal 
surgical parathyroidectomy should also be discussed in case 
of persistent and uncontrolled hypercalcemia, hyperphos-
phatemia, and high serum PTH levels, as well as in cases of 
progressive vascular calcifications, calciphylaxis, multiple 
skeletal fractures, and cardiac complications (Fig. 2).
The more challenging situation is the treatment of 
patients with low PTH. The restoration of PTH levels to the 
“2–9 time-fold” target is recommended to ensure a proper 
function of bone cells and a replacement of old to new bone 
matrix. This could be achieved by reducing calcium load 
either through the diet or lowering calcium content in the 
dialysate [101]. More specific anti-resorbing therapy may 
promote adynamic bone disease and the emergence of vas-
cular calcifications. However, denosumab does not induce 
any aortic calcifications in postmenopausal women without 
renal failure [102] and there are no data in humans show-
ing that reducing bone turnover would increase the risk of 
vascular calcifications. In addition, denosumab reduces the 
deposition of calcium in vessels of osteopenic mice [103]. 
Further studies are needed to determine whether this drug 
has an impact on vascular calcifications in CKD.
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To the best of knowledge, the optimal therapy for CKD-
associated osteoporosis would be a drug that enhances bone 
formation and restores bone mass. In this sense, the effect of 
teriparatide has been evaluated in a small pilot study includ-
ing 7 hemodialysis patients. There was a significant increase 
in lumbar and femoral BMD after 6 months of treatment and 
in 6 out of the 7 patients [104]. However, we are lacking evi-
dence regarding the effect of teriparatide on the prevention 
of fractures in advanced CKD. Anti-sclerostin antibody is a 
promising anabolic agent as it promotes bone formation by 
binding to sclerostin, a natural antagonist of Wnt signaling. 
Indeed, romosozumab increased BMD and prevents bone 
fractures in postmenopausal women without CKD [105]. 
Interestingly, anti-sclerostin antibody increases bone forma-
tion and bone mass in rats with CDK only with low, but not 
with high PTH [106]. Trials based on this promising therapy 
in CKD are highly awaited taking into account the alert on 
the possible cardiovascular side effects.
In conclusion, the high incidence of fractures and mor-
tality in patients with CKD requires a better evaluation of 
fracture risk, as well as more randomized controlled trials on 
fracture prevention. Because of the multiple aspects of bone 
fragility in CKD, a multidisciplinary discussion including 
renal and bone experts in CKD-MBD would be desirable 
before any initiation of specific bone treatments.
Fig. 1  Pathophysiology of fractures in CKD. Schematic representation of the changes induced by CKD: 25OHD 25hydroxy-vitamin D; 
1,25(OH)2 D: 1–25 dihydroxy-vitamin D. PTH parathyroid hormone; Wnt wintless
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